Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban

Thrombosis Research

Volumn 153, Issue , 2017, Pages 37-39

  Crowley, Maeve P ^a   Cuadrado, Maria J ^a   Hunt, Beverley J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; RIVAROXABAN; STEROID; TROPONIN; WARFARIN; ANTICOAGULANT AGENT;

ADDISON DISEASE; ADRENAL DISEASE; ADRENAL HEMORRHAGE; ADRENAL THROMBOSIS; ADULT; AMBIENT AIR; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPOKINESIA; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LETTER; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MICROANGIOPATHY; MYOCARDIAL DISEASE; OXYGEN TENSION; PLEURA EFFUSION; PRIORITY JOURNAL; SECONDARY PREVENTION; ST SEGMENT ELEVATION; SUBSTITUTION THERAPY; TERMINAL DISEASE; THORAX PAIN; THROMBOSIS PREVENTION; THROMBOTIC MYOCARDIAL MICROANGIOPATHY; TREATMENT DURATION; PATHOLOGY;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; RIVAROXABAN; WARFARIN;

EID: 85015707473     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.03.006     Document Type: Letter

References (10)

1. [1] Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R., Mackie, I.J., Clawson, S., et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 3:9 (2016), e426–e436.
2. [2] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:2 (2006), 295–306.
3. [3] Cervera, R., Font, J., Gomez-Puerta, J.A., Espinosa, G., Cucho, M., Bucciarelli, S., et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann. Rheum. Dis. 64:8 (2005), 1205–1209.
4. [4] Cervera, R., Rodriguez-Pinto, I., Colafrancesco, S., Conti, F., Valesini, G., Rosario, C., et al. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun. Rev. 13:7 (2014), 699–707.
5. [5] Sciascia, S., Lopez-Pedrera, C., Cecchi, I., Pecoraro, C., Roccatello, D., Cuadrado, M.J., Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology (Oxford) 55:10 (2016 Oct), 1726–1735.
6. [6] Noel, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun. Rev. 14:8 (2015), 680–685.
7. [7] Haladyj, E., Olesinska, M., Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia 54:3 (2016), 146–149.
8. [8] Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A., Levy, R.A., Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin. Rheumatol. 35:3 (2016), 801–805.
9. [9] Schaefer, J.K., McBane, R.D., Black, D.F., Williams, L.N., Moder, K.G., Wysokinski, W.E., Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb. Haemost. 112:5 (2014), 947–950.
10. [10] Dufrost, V., Risse, J., Zuily, S., Wahl, D., Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr. Rheumatol. Rep., 18(12), 2016, 74.